Supplementary Materials

Supplementary Material for:

Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk

Douglas Moeckel, Soon Soeg Jeong, Xiaofeng Sun, M. Johan Broekman, Annie Nguyen, Joan H. F. Drosopoulos, Aaron J. Marcus, Simon C. Robson, Ridong Chen,* Dana Abendschein*

*Corresponding author. E-mail: rchen@apt-therapeutics.com (R.C.); dabendsc@DOM.wustl.edu (D.A.)

Published 6 August 2014, Sci. Transl. Med. 6, 248ra105 (2014)
DOI: 10.1126/scitranslmed.3009246

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Design of human ADPase-enhanced apyrases.
  • Fig. S2. Comparison of the enzymatic activities of APT102 and solCD39.
  • Fig. S3. Inhibition by APT102 of ADP-induced aggregation in human plateletrich plasma.
  • Fig. S4. In vitro inhibition by APT102 of ADP-induced aggregation of rabbit, pig, and dog platelet-rich plasma.
  • Fig. S5. Effects of clopidogrel and prasugrel prodrugs on inhibition of ADPinduced aggregation of canine platelet-rich plasma achieved with recombinant solCD39 and APT102.
  • Fig. S6. Purification of APT102 from the supernatant of CHO cells stably transfected with the APT102 gene.
  • Fig. S7. Pharmacokinetics of APT102 in dogs.
  • Fig. S8. Pharmacodynamics of APT102 and clopidogrel in dogs.
  • Fig. S9. Experiment protocol for dogs undergoing coronary occlusion and fibrinolysis.
  • Fig. S10. Coronary artery blood flow in dogs before and after occlusion and fibrinolysis.
  • Fig. S11. Bleeding times in mice after clopidogrel with or without added APT102.
  • Table S1. Kinetic parameters of wild-type and mutant solCD39L3 and solCD39 toward ADP and ATP.
  • Table S2. In vitro inhibition of ADP-induced platelet aggregation with APT102.
  • Table S3. Coagulation parameters versus time after coronary occlusion and fibrinolysis in dogs.
  • Table S4. Hematologic values at baseline and 24 hours after coronary occlusion and fibrinolysis in individual dogs.
  • Table S5. Serum chemistry values at baseline and 24 hours after coronary occlusion and fibrinolysis in individual dogs.
  • References (4951)

[Download PDF]